Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

1.

TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes.

Choi SW, Stiff P, Cooke K, Ferrara JL, Braun T, Kitko C, Reddy P, Yanik G, Mineishi S, Paczesny S, Hanauer D, Pawarode A, Peres E, Rodriguez T, Smith S, Levine JE.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1525-32. doi: 10.1016/j.bbmt.2012.03.013. Epub 2012 Mar 30.

PMID:
22469883
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.

Strober S.

Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. Epub 2007 Sep 10. Review.

PMID:
17827036
[PubMed - indexed for MEDLINE]
4.

Non-myeloablative transplants for malignant disease.

Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH.

Hematology Am Soc Hematol Educ Program. 2001:375-91. Review.

PMID:
11722994
[PubMed - indexed for MEDLINE]
Free Article
5.

Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.

Wahid SF.

Int J Hematol. 2013 May;97(5):581-98. doi: 10.1007/s12185-013-1313-0. Epub 2013 Apr 13. Review.

PMID:
23585244
[PubMed - indexed for MEDLINE]
6.

Have we made progress in the treatment of GVHD?

Harris AC, Levine JE, Ferrara JL.

Best Pract Res Clin Haematol. 2012 Dec;25(4):473-8. doi: 10.1016/j.beha.2012.10.010. Epub 2012 Oct 25. Review.

PMID:
23200544
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk